Can removing certain immune cells make stem cell transplants safer for myeloma patients?

NCT ID NCT01526096

Completed Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested whether removing a specific type of immune cell (regulatory T cells) is safe in 30 people with multiple myeloma undergoing a stem cell transplant. Participants received standard transplant drugs plus a procedure to deplete these cells. The goal was to see if this could reduce complications like graft-versus-host disease. The study is complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: G-CSF, plerixafor, melphalan, and regulatory T cell depletion
What this could lead to: If successful, this approach could improve the safety and effectiveness of stem cell transplants for multiple myeloma by reducing harmful immune reactions.
What could go wrong: This is a very early (Phase 1) pilot study with only 30 participants, so results may not apply broadly. The T cell depletion could also increase infection risk or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOMA

Contacts and locations

Show contact details

Locations

University of Chicago

Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.